FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130657032> ?p ?o ?g. }

• W2130657032 endingPage "1790" @default.
• W2130657032 startingPage "1784" @default.
• W2130657032 abstract "Objective— This study aims to evaluate the relationship between tissue advanced glycation end products, as reflected by skin autofluorescence, and vascular calcification in chronic kidney disease. Approach and Results— Three hundred patients with stage 3 to 5 chronic kidney disease underwent multislice computed tomography to estimate total coronary artery calcium score (CACS) and had tissue advanced glycation end product assessed using a skin autofluorescence reader. Intact parathyroid hormone ( P <0.001) displaced estimated glomerular filtration rate as third most significant factor associated with skin autofluorescence after age ( P <0.001) and diabetes mellitus ( P <0.001) in multiple regression analysis. On univariate multinomial logistic regression analysis, every 1-U increase in skin autofluorescence was associated with a 7.43-fold (95% confidence intervals, 3.59–15.37; P <0.001) increased odds of having CACS ≥400 compared with those with zero CACS. Skin autofluorescence retained significance in predicting CACS ≥400 (odds ratio, 3.63; 95% confidence intervals, 1.44–9.18; P =0.006) when adjusting for age, sex, serum calcium, phosphate, albumin, C-reactive protein, lipids, blood pressure, estimated glomerular filtration rate, and intact parathyroid hormone but marginally lost significance when additionally adjusting for diabetes mellitus (odds ratio, 2.23; 95% confidence intervals, 0.81–6.14; P =0.1). Combination of diabetes mellitus and higher intact parathyroid hormone was associated with greater skin autofluorescence and CACS versus those without diabetes mellitus and having lower intact parathyroid hormone. Conclusions— Tissue advanced glycation end product, as reflected by skin autofluorescence, showed a significant novel association with vascular calcification in chronic kidney disease. These data suggest that increased tissue advanced glycation end product may contribute to vascular calcification in chronic kidney disease and diabetes mellitus and warrant further experimental investigation." @default.
• W2130657032 created "2016-06-24" @default.
• W2130657032 creator A5021505421 @default.
• W2130657032 creator A5032309012 @default.
• W2130657032 creator A5048145208 @default.
• W2130657032 creator A5050890481 @default.
• W2130657032 creator A5063663865 @default.
• W2130657032 creator A5075382903 @default.
• W2130657032 date "2014-08-01" @default.
• W2130657032 modified "2023-10-16" @default.
• W2130657032 title "Skin Autofluorescence Associates With Vascular Calcification in Chronic Kidney Disease" @default.
• W2130657032 cites W1564602063 @default.
• W2130657032 cites W1905586581 @default.
• W2130657032 cites W1964465210 @default.
• W2130657032 cites W1966234811 @default.
• W2130657032 cites W1971886163 @default.
• W2130657032 cites W1982878086 @default.
• W2130657032 cites W1988687462 @default.
• W2130657032 cites W2001320633 @default.
• W2130657032 cites W2002616153 @default.
• W2130657032 cites W2006633923 @default.
• W2130657032 cites W2023406744 @default.
• W2130657032 cites W2024861061 @default.
• W2130657032 cites W2037786457 @default.
• W2130657032 cites W2038676563 @default.
• W2130657032 cites W2042854938 @default.
• W2130657032 cites W2056010931 @default.
• W2130657032 cites W2056153956 @default.
• W2130657032 cites W2068900191 @default.
• W2130657032 cites W2081901990 @default.
• W2130657032 cites W2085314827 @default.
• W2130657032 cites W2088850537 @default.
• W2130657032 cites W2115102916 @default.
• W2130657032 cites W2117789281 @default.
• W2130657032 cites W2122567972 @default.
• W2130657032 cites W2129984493 @default.
• W2130657032 cites W2134064184 @default.
• W2130657032 cites W2140905655 @default.
• W2130657032 cites W2153288821 @default.
• W2130657032 cites W2158942749 @default.
• W2130657032 cites W2163425767 @default.
• W2130657032 cites W2164553737 @default.
• W2130657032 cites W2166731834 @default.
• W2130657032 cites W2335364913 @default.
• W2130657032 doi "https://doi.org/10.1161/atvbaha.114.303378" @default.
• W2130657032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24876353" @default.
• W2130657032 hasPublicationYear "2014" @default.
• W2130657032 type Work @default.
• W2130657032 sameAs 2130657032 @default.
• W2130657032 citedByCount "24" @default.
• W2130657032 countsByYear W21306570322015 @default.
• W2130657032 countsByYear W21306570322016 @default.
• W2130657032 countsByYear W21306570322017 @default.
• W2130657032 countsByYear W21306570322018 @default.
• W2130657032 countsByYear W21306570322019 @default.
• W2130657032 countsByYear W21306570322020 @default.
• W2130657032 countsByYear W21306570322021 @default.
• W2130657032 countsByYear W21306570322022 @default.
• W2130657032 countsByYear W21306570322023 @default.
• W2130657032 crossrefType "journal-article" @default.
• W2130657032 hasAuthorship W2130657032A5021505421 @default.
• W2130657032 hasAuthorship W2130657032A5032309012 @default.
• W2130657032 hasAuthorship W2130657032A5048145208 @default.
• W2130657032 hasAuthorship W2130657032A5050890481 @default.
• W2130657032 hasAuthorship W2130657032A5063663865 @default.
• W2130657032 hasAuthorship W2130657032A5075382903 @default.
• W2130657032 hasBestOaLocation W21306570321 @default.
• W2130657032 hasConcept C121332964 @default.
• W2130657032 hasConcept C126322002 @default.
• W2130657032 hasConcept C134018914 @default.
• W2130657032 hasConcept C142724271 @default.
• W2130657032 hasConcept C156957248 @default.
• W2130657032 hasConcept C159641895 @default.
• W2130657032 hasConcept C179687394 @default.
• W2130657032 hasConcept C2778653478 @default.
• W2130657032 hasConcept C2781208988 @default.
• W2130657032 hasConcept C519063684 @default.
• W2130657032 hasConcept C555293320 @default.
• W2130657032 hasConcept C62520636 @default.
• W2130657032 hasConcept C71924100 @default.
• W2130657032 hasConcept C90924648 @default.
• W2130657032 hasConcept C91881484 @default.
• W2130657032 hasConceptScore W2130657032C121332964 @default.
• W2130657032 hasConceptScore W2130657032C126322002 @default.
• W2130657032 hasConceptScore W2130657032C134018914 @default.
• W2130657032 hasConceptScore W2130657032C142724271 @default.
• W2130657032 hasConceptScore W2130657032C156957248 @default.
• W2130657032 hasConceptScore W2130657032C159641895 @default.
• W2130657032 hasConceptScore W2130657032C179687394 @default.
• W2130657032 hasConceptScore W2130657032C2778653478 @default.
• W2130657032 hasConceptScore W2130657032C2781208988 @default.
• W2130657032 hasConceptScore W2130657032C519063684 @default.
• W2130657032 hasConceptScore W2130657032C555293320 @default.
• W2130657032 hasConceptScore W2130657032C62520636 @default.
• W2130657032 hasConceptScore W2130657032C71924100 @default.
• W2130657032 hasConceptScore W2130657032C90924648 @default.
• W2130657032 hasConceptScore W2130657032C91881484 @default.
• W2130657032 hasIssue "8" @default.

• next